13251-86-0 Usage
Uses
Used in Bodybuilding and Athletic Performance Enhancement:
(6alpha,17beta)-17-hydroxy-6-methylandrost-4-en-3-one is utilized as a performance-enhancing substance for athletes and bodybuilders. It is employed to increase muscle mass, improve physical strength, and elevate overall athletic performance. However, its use is controversial due to the potential for side effects and is subject to regulation to ensure fair competition and safeguard the health of athletes.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (6alpha,17beta)-17-hydroxy-6-methylandrost-4-en-3-one may be used as an active ingredient in the development of medications aimed at treating conditions related to muscle wasting or other muscle-related disorders. Its anabolic properties make it a potential candidate for therapeutic applications, provided that the risks and benefits are carefully evaluated and managed.
Check Digit Verification of cas no
The CAS Registry Mumber 13251-86-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,2,5 and 1 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 13251-86:
(7*1)+(6*3)+(5*2)+(4*5)+(3*1)+(2*8)+(1*6)=80
80 % 10 = 0
So 13251-86-0 is a valid CAS Registry Number.
13251-86-0Relevant academic research and scientific papers
ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT
-
, (2008/06/13)
The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.
TRANSDERMAL ADMINISTRATION OF MENT
-
, (2008/06/13)
The present invention relates to transdermal dosage forms for delivery of androgens.
Method for androgen supplementation
-
, (2008/06/13)
A particular group of androgens is not metabolized to their 5α-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6α or 7α position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7α-methyl-19-nortestosterone.
